AstraZeneca secures Nona’s antibody assets to boost oncology portfolio
License out/inADC
AstraZeneca is looking to augment its targeted oncology portfolio by tapping into Nona Biosciences’ preclinical monoclonal antibody (mAb) assets through a global licensing agreement.
Under the deal announced Wednesday, AstraZeneca will pay Nona $19 million upon completing the transaction, with the latter eligible for near-term payments of up to $10 million and additional milestones payments of as much as $575 million. Nona is also entitled to receive tiered sales royalties, alongside payments for the option programmes if AstraZeneca chooses to exercise them.
Nona employs an "Idea to IND" approach, encompassing target validation, antibody discovery, and preclinical research to develop fully-human mAbs with its Harbour Mice platform. “This agreement further validates our leading antibody discovery platform, and we look forward to seeing our antibodies developed into potential new medicines,” said Nona chairman Jingsong Wang.
Puja Sapra, SVP tumour targeted therapy at AstraZeneca, added that the deal presents them “an exciting opportunity to further develop these antibodies.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.